MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Companys LED-based Photobiomodulation Therapy Device

▤ Summary

MuReva Phototherapy announced positive clinical data for its LED-based photobiomodulation therapy device at the 2025 ASTRO Meeting. The study showed the device was safe, well tolerated, and effective at reducing severe oral mucositis in head and neck cancer patients receiving radiation therapy. Patients using the device also reported less mouth and throat soreness, less taste loss, and a lower need for feeding tubes. The company says the mouthpiece-based system automates treatment and makes delivery faster and easier than older laser or LED probe approaches.

▦ Linked Companies